Exact Sciences Intrinsic Value Calculation – Exact Sciences Co. Receives ‘Moderate Buy’ Recommendation from Brokerages
January 4, 2024
🌥️Trending News
Exact Sciences ($NASDAQ:EXAS) Co. recently received a ‘Moderate Buy’ recommendation from several brokerages. This is an average recommendation indicating that investors should consider buying the company’s stock. Exact Sciences is a leading molecular diagnostics testing company based in Wisconsin. It is best known for its Cologuard, a non-invasive, stool DNA screening test for colorectal cancer.
The company also offers other diagnostic products and services. Shares of Exact Sciences have seen an impressive rally over the past year, and the analyst’s recommendation could be seen as further validation for the company’s growth potential. With its innovative products and expanding markets, Exact Sciences could be well positioned to continue delivering strong results in the coming years.
Share Price
On Tuesday, shares of Exact Sciences Co. (EXACT SCIENCES) opened at $73.5 and closed at $73.8, down by 0.3% from the previous closing price of $74.0. This dip followed a recent ‘Moderate Buy’ recommendation from various brokerages, which has seen the stock trending upwards in the last few months. The recommendation comes on the back of reports that suggest the company’s recent technological developments and expansions are set to increase its overall growth. With the stock trading at a reasonable price, analysts seem to be bullish on the future prospects of EXACT SCIENCES. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Exact Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 2.41k | -282.13 | -350.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Exact Sciences. More…
| Operations | Investing | Financing |
| 138.61 | 58.29 | 159.83 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Exact Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.42k | 3.3k | 17.26 |
Key Ratios Snapshot
Some of the financial key ratios for Exact Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 22.1% | – | 214.9% |
| FCF Margin | ROE | ROA |
| -1.0% | 104.6% | 50.3% |
Analysis – Exact Sciences Intrinsic Value Calculation
At GoodWhale, we analyze the financials of EXACT SCIENCES to provide investors with valuable insights into its performance. Upon examining the financials of the company, we have calculated its intrinsic value to be around $96.1 using our proprietary Valuation Line. At the present moment, EXACT SCIENCES is trading at $73.8, which is significantly below its intrinsic value and thus represents an incredible opportunity for investors to capitalize on an undervalued stock. This presents a potential 23.2% upside for investors who are able to seize this opportunity. More…
Peers
The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.
– Inoviq Ltd ($ASX:IIQ)
Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.
Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.
– Myriad Genetics Inc ($NASDAQ:MYGN)
Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.
Summary
Exact Sciences Co. has recently been given an average recommendation of “Moderate Buy” from brokerages. Investors are cautiously optimistic when it comes to the stock, with the majority of analysts recommending that investors should at least consider buying the stock. For those interested in investing in Exact Sciences Co., the current outlook indicates that there may be potential for moderate returns. While there is always inherent risk when investing, analysts are confident that the stock may offer investors a moderate level of growth in the future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
